Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed)

Active
Yes
Status
Posted
Published Date
January 25th, 2024
Close Date
May 31st, 2024
Award Ceiling
$350,000.00
Opportunity No.
RFA-AI-24-003

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) has posted a grant opportunity titled "Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed)". This grant aims to support radiation research for the identification of biomarkers of injury and the development of assays or devices for triage purposes. The goal is to assess absorbed dose or predict health outcomes of acute or delayed injuries resulting from radiation exposure during a public health emergency. The funding opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The maximum award ceiling for this grant is $350,000. For more information and to apply, visit the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-003.html.

Description

The purpose of this notice of funding opportunity (NOFO) is to support radiation research at all stages of development for the identification of biomarkers of injury and the development of assays or devices for the purpose of triage, including assessing absorbed dose or predicting health outcomes of acute or delayed injuries resulting from radiation exposure during a public health emergency. This NOFO will support the development of these approaches, with the goal of future regulatory approval.

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)". This grant aims to support research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit for the development of new and effective anticancer treatments. The grant does not require cost sharing or matching. The maximum award ceiling is $275,000. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities, Indian/Native American Tribal Governments, Non-domestic (non-U.S.) Entities, Regional Organizations, Tribally Controlled Colleges and Universities, and U.S. Territories or Possessions. The closing date for applications is September 7, 2025. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html). For any inquiries, contact NIH OER Webmaster at OERWebmaster03@od.nih.gov.
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)". This grant opportunity falls under the category of Health and is a discretionary grant. The grant does not require cost sharing or matching. The purpose of this grant is to accelerate the translation of NCI-supported methods/assays/technologies to the clinic, specifically focusing on the adaptation and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. The grant encourages multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. The grant does not support early-stage development of technology or the conduct of clinical trials, but rather the adaptation and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices. The grant has a closing date of October 13, 2026, and an award ceiling of $150,000. For more information and to apply, visit the following link: [Additional Information](http://grants.nih.gov/grants/guide/pa-files/PAR-24-047.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)". This grant aims to support extramural research in investigating and mitigating challenges faced in clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies, or other biospecimens. The research funded under this grant will explore the preanalytical variability associated with the procurement and study of various biospecimens, such as small biopsies, blood, tissue swabs, tissue secretions, and bodily fluids. The goal is to improve the understanding of how different preanalytical conditions affect biomarkers and to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices. The grant does not require cost sharing or matching and falls under the category of health. The deadline for application submission is September 13, 2024. For more information and to apply, visit the following link: [Integrating Biospecimen Science Approaches into Clinical Assay Development Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-22-049.html).